› 5h7h

X-ray diffraction
1.95Å resolution

Crystal structure of the BCL6 BTB domain in complex with F1324(10-13)

Released:
DOI: 10.2210/pdb5h7h/pdb
PDB entry 5h7h coloured by chain, front view.
PDB entry 5h7h coloured by chain, side view.
PDB entry 5h7h coloured by chain, top view.
Source organisms:
Primary publication:
Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship.
Sakamoto K, Sogabe S, Kamada Y, Sakai N, Asano K, Yoshimatsu M, Ida K, Imaeda Y, Sakamoto JI
Biochem Biophys Res Commun 482 310-316 (2017)
PMID: 27856253

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero hexamer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-154265 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
B-cell lymphoma 6 protein Chain: A
Molecule details ›
Chain: A
Length: 141 amino acids
Theoretical weight: 16.29 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P41182 (Residues: 5-129; Coverage: 18%)
Gene names: BCL5, BCL6, LAZ3, ZBTB27, ZNF51
Sequence domains: BTB/POZ domain
Structure domains: Potassium Channel Kv1.1; Chain A
F1324 peptide residues 10-13 Chains: B, C
Molecule details ›
Chains: B, C
Length: 5 amino acids
Theoretical weight: 584 Da
Source organism: Escherichia phage T7
Expression system: Not provided

Ligands and Environments

1 bound ligand:
Ligand EDO 1 x EDO
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: PHOTON FACTORY BEAMLINE AR-NE3A
Spacegroup: P6122
Unit cell:
a: 67.398Å b: 67.398Å c: 166.725Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.192 0.19 0.227
Expression systems:
  • Escherichia coli
  • Not provided

Quick links

Citations

3 review citations

Targeting Transcription Factors for Cancer Treatment.
Lambert et al. (2018)
2 more

1 mention without citation

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai et al. (2021)